<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02472964</url>
  </required_header>
  <id_info>
    <org_study_id>MYL-Her3001</org_study_id>
    <secondary_id>2011-001965-42</secondary_id>
    <nct_id>NCT02472964</nct_id>
  </id_info>
  <brief_title>Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca.</brief_title>
  <acronym>HERiTAge</acronym>
  <official_title>A Multicenter, Double-Blind, Randomized, Parallel-Group, Phase III Study To Compare The Efficacy And Safety Of Hercules Versus Herceptin® In Patients With HER2+ Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mylan Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mylan GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mylan Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, double-blind, randomized, parallel-group, Phase III study of the efficacy and
      safety of Hercules( Myl 1401O, Mylan Trastuzumab) plus taxane versus Herceptin® plus taxane
      as first line therapy in patients with HER2-positive metastatic breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1: A multicenter, double-blind, randomized, parallel-group, Phase III study to compare
      the efficacy and safety of Hercules( Myl 1401O, Mylan Trastuzumab) plus taxane versus
      Herceptin® plus taxane in patients with HER2+ MBC. Either docetaxel or paclitaxel
      (Investigator site level choice) is planned for at least 24 weeks until documented response
      to therapy, disease progression, or discontinuation. Disease response and progression will be
      assessed locally by the Investigator on the basis of clinical and radiographic evidence using
      RECIST 1.1 criteria. The primary and secondary efficacy analyses will be performed using
      independently assessed radiographic evidence for the Intent-to-Treat (ITT) population. The
      primary analysis population for best ORR will be those patients who had measureable disease
      at baseline and for the secondary endpoint, DR, only those who are responders will be
      included in the analysis.

      Part 2: A multicenter, double-blind, parallel-group study to continue to compare the safety
      and immunogenicity and efficacy of Hercules( Myl 1401O, Mylan Trastuzumab) versus Herceptin®
      in patients with HER2+ MBC who have clinical benefit to first-line combination therapy with a
      taxane. All patients who have at least stable disease (SD), will continue with either single
      agent Hercules( Myl 1401O, Mylan Trastuzumab) or Herceptin® alone until death, unacceptable
      toxicity or disease progression.

      Population pharmacokinetics: During Part 1 of the study, for both the Hercules ( Myl 1401O,
      Mylan Trastuzumab)and Herceptin® treatment arms, PK sampling for Cmin and Cmax (end of
      infusion) will be collected for all patients. A PopPK subset, with sufficient samples
      available to perform the necessary analysis of PopPK modeling will be used to assess AUC,
      Cmax, Cmin, clearance, Vd, and T1/2 at various time points in the PopPK. Patients randomized
      into the main study will sign an additional consent form for the PopPK subset. We anticipate
      that approximately 80 patients will need to be enrolled in this subset collection in order to
      obtain sufficient samples for analysis.

      Long term survival follow-up: OS for this treated population will be determined with every 3
      month follow-up until either 240 deaths or 36 months, whichever occurs first, as observed
      from the time of randomization.

      Exploratory evaluations: In addition, during Part 1 of the study, blood samples will be
      collected in all patients to assess the impact of soluble shed HER2/ECD on PK and efficacy at
      pre-dose on Cycles 1, 3, 5, 7, and end of treatment (EOT). Additional samples (ECD) will be
      obtained on Cycles 9, 13 and every 4 cycles thereafter, EOT and end of study (EOS) for
      continued evaluation of immunogenicity in patients continuing to receive therapy. A blood
      sample will be obtained on Cycle 1, Day 1, to be used for assay development and validation
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>compare best overall response rate (ORR) (according to Response Evaluation Criteria in Solid Tumor [RECIST] 1.1 criteria) at Week 24 with Hercules( Myl 1401O, Mylan Trastuzumab) in combination with taxane versus Herceptin® plus taxane</measure>
    <time_frame>from time of First treatment to week 24</time_frame>
    <description>RECIST 1.1 evaluation for overall response rate at 6 week intervals</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to tumor progression (TTP);</measure>
    <time_frame>from time of first treatment to week 24 at every 6 week intervals</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>•overall survival (OS)</measure>
    <time_frame>from time of first treatment to week 24 at every 6 week intervals</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response (DR).</measure>
    <time_frame>from time of first treatment to week 24 at every 6 week intervals</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Herceptin© + Taxane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Part 1: Herceptin© (trastuzumab) intravenously+ paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint.
Part 2: If SD or PR, CR at cycle 9 (week 24) proceed to Herceptin© (trastuzumab) alone once every 3 weeks until DP or subject withdrawal .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HerMyl 1401O Trastuzumab + Taxane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1:Myl 1401OTrastuzumab Intravenously + paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint.
Part 2: If SD or PR, CR at cycle 9 (week 24) proceed to Myl 1401O( Mylan Trastuzumab) alone once every 3 weeks until DP or subject withdrawal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Trastuzumab 8mg/kg Iv over 90 minutes x 1 then Trastuzumab 6 mg/kg IV over 30 minutes every 3 weeks</description>
    <arm_group_label>Herceptin© + Taxane</arm_group_label>
    <other_name>Herceptin©;</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HERMyl 1401O Trastuzumab</intervention_name>
    <description>HERMyl 1401O Trastuzumab 8mg/kg Iv over 90 minutes x 1 then HERMyl 1401O Trastuzumab 6 mg/kg IV over 30 minutes every 3 weeks</description>
    <arm_group_label>HerMyl 1401O Trastuzumab + Taxane</arm_group_label>
    <other_name>Hercules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel 80mg/m2 IV over 60 minutes weekly.</description>
    <arm_group_label>Herceptin© + Taxane</arm_group_label>
    <arm_group_label>HerMyl 1401O Trastuzumab + Taxane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel 75mg/m2 IV over 60 minutes on day 1 of a 3 week cycle</description>
    <arm_group_label>Herceptin© + Taxane</arm_group_label>
    <arm_group_label>HerMyl 1401O Trastuzumab + Taxane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Locally recurrent or MBC that is not amenable to curative surgery and/or radiation.

        Documentation of HER2 gene amplification by fluorescent in situ hybridization (FISH) (as
        defined by a ratio &gt;2.0) or documentation of HER2-overexpression by immunohistochemistry
        (IHC) (defined as IHC3+, or IHC2+ with FISH confirmation) based on the sponsor-identified
        central laboratory prior to randomization. Archival tumor tissue samples can be used.

        Pathologically confirmed breast cancer with at least one measurable metastatic target
        lesion (based on RECIST criteria, version 1.1). Bone, central nervous system (CNS), and
        skin lesions, as well as lesions that were irradiated, biopsied or had any form of local
        intervention or surgical manipulation are only to be assessed as non-target lesions.

        Patients previously treated with trastuzumab or lapatinib in the adjuvant setting are
        allowed if metastatic disease was diagnosed at least one year after the last dose of
        treatment.

        Prior treatment with hormonal agents or bisphosphonates/denosumab is allowed.
        Bisphosphonates/denosumab can be given simultaneously with study treatment but cannot start
        after randomization and is considered an indication of progressive disease (PD). Hormonal
        agents must be discontinued prior to beginning study therapy.

        Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 - 2

          -  Serum creatinine ≤1.5 x ULN (upper limit of normal),

          -  Total bilirubin ≤1.0 x ULN (&gt;1.0 x ULN if documented Gilbert's disease),

          -  Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) ≤2.5 x ULN,

          -  AST and/or ALT &lt;1.5 x ULN if alkaline phosphatase &gt;2.5 x ULN,

          -  Alkaline phosphatase &gt;2.5 x ULN;if bone metastases present and no liver dysfunction
             present.

        Left ventricular ejection fraction (LVEF) within institutional range of normal as measured
        by multiple gated acquisition scan or echocardiogram.

        Exclusion Criteria:

        Prior systemic therapy in the metastatic disease setting. This includes: chemotherapy,
        signal transduction inhibitors (e.g., lapatinib), HER2 targeted therapy (e.g.,
        trastuzumab), or other investigational anticancer therapy.

        Prior treatment with neoadjuvant or adjuvant anthracyclines with a cumulative dose of
        doxorubicin of &gt;400 mg/m2, epirubicin dose &gt;800 mg/m2.

        Patients with bone or skin as the only site of disease. Patients with skin lesions
        measurable by CT scans or MRI as only site of measurable disease are allowed.

        Surgery or radiotherapy ≤2 weeks preceding Day 1. Target lesions have to be outside the
        irradiated fields and the patient has fully recovered from surgery or radiotherapy.

        Presence of unstable angina or a history of congestive heart failure according to the New
        York Heart Association criteria, history of myocardial infarction &lt;1 year from
        randomization, clinically significant valvular disease, serious cardiac arrhythmia
        requiring treatment, uncontrolled hypertension or known pulmonary hypertension.

        Peripheral sensory or motor neuropathy Grade 2 or higher according to the National Cancer
        Institute-Common Terminology Criteria (NCI-CTC) Version 4.03 [19].

        Any other cancer, including contralateral breast cancer, within 5 years prior to screening
        with the exception of adequately treated ductal carcinoma in situ, adequately treated
        cervical carcinoma in situ, or adequately treated basal or squamous cell carcinoma of the
        skin.

        Immunocompromized patients, including known seropositivity for human immunodeficiency
        virus, or current or chronic hepatitis B and/or hepatitis C infection (as detected by
        positive testing for hepatitis B surface antigen or antibody to hepatitis C virus with
        confirmatory testing).

        Complete listing of Inc/Excl. within protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo Pennella, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mylan Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Barretos</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Brasilia</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Goiania</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Ijui</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Jau</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Joinville</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Morumbi</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Salvador,</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Santo Andre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Sorocaba</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Temuco</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Batumi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Tblisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Gyod</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Gyula</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Nyiregyhaza</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Szekszard</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Szolnok</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Ahmedabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Gurgaon</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Karamsad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Madurai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Nashik</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Surat</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Vijaywada</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Daugavpils</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Leipaja</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Arequipa</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Surquillo</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Cluj- Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Constanta</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Craiva</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Filimon Sirbu</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Oradea</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Arkhangelsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Ivanovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Kursk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Rostov-On-Don</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Ryazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Kamenica</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Sremska</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Bardejov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Nove Zamky</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Trnava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Bloemfontein</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>George</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Kraaifontein</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Port Elizabeth</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigational Site</name>
      <address>
        <city>Vereeniging</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Chiang mai</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Phitsanulok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Rajthavee</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Songkla</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Kocaeli</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Cherkassy</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Chernivtsi</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Lutsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Sumy</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mylan Investigator Site</name>
      <address>
        <city>Uzhgorod</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Chile</country>
    <country>Georgia</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Latvia</country>
    <country>Peru</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2015</study_first_submitted>
  <study_first_submitted_qc>June 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2015</study_first_posted>
  <last_update_submitted>May 12, 2016</last_update_submitted>
  <last_update_submitted_qc>May 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Taxane</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 12, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

